Authors: Lindsay, KL Trepo, C Heintges, T Shiffman, ML Gordon, SC Hoefs, JC Schiff, ER Goodman, ZD Laughlin, M Yao, RJ Albrecht, JK

Citation: Kl. Lindsay et al., A randomized, double-blind trial comparing pegylated interferon alfa-2b tointerferon alfa-2b as initial treatment for chronic hepatitis C, HEPATOLOGY, 34(2), 2001, pp. 395-403

Authors: Emilie, D Burgard, M Lascoux-Combe, C Laughlin, M Krzysiek, R Pignon, C Rudent, A Molina, JM Livrozet, JM Souala, F Chene, G Grangeot-Keros, L Galanaud, P Sereni, D Rouzioux, C

Citation: D. Emilie et al., Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study, AIDS, 15(11), 2001, pp. 1435-1437

Authors: Kim, H Lin, CC Laughlin, M Lovey, R Saksena, A Heimark, L Nomeir, AA

Citation: H. Kim et al., Chiral high-performance liquid chromatographic analysis of antifungal SCH 56592 and evaluation of its chiral inversion in animals and humans, CHIRALITY, 12(7), 2000, pp. 590-597

Authors: Koc, ON Gerson, SL Cooper, BW Laughlin, M Meyerson, H Kutteh, L Fox, RM Szekely, EM Tainer, N Lazarus, HM

Citation: On. Koc et al., Randomized cross-over trial of progenitor-cell mobilization: High-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF, J CL ONCOL, 18(9), 2000, pp. 1824-1830

Authors: Laughlin, M

Citation: M. Laughlin, Packaging revolution spearheads shrinking or analog products, ELECTR PROD, 1999, pp. 27-28